ProQR Therapeutics (PRQR) Income from Non-Controlling Interests (2017 - 2023)
ProQR Therapeutics recorded quarterly Income from Non-Controlling Interests of $315691.2 in Q3 2023, up 1711.94% quarter-over-quarter from $17422.8 in Q2 2023, and up 2136.43% year-over-year from $14115.8 in Q3 2022.
ProQR Therapeutics' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at $315691.2 for Q3 2023.
- In Q3 2023, Income from Non-Controlling Interests rose 2136.43% year-over-year to $315691.2; the TTM figure through Dec 2023 stood at $416834.7 (up 78.42% YoY), while the FY2023 annual figure was $413160.9, up 84.07% from the prior year.
- Income from Non-Controlling Interests came in at $315691.2 for Q3 2023 at ProQR Therapeutics, up from $17422.8 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $315691.2 in Q3 2023 to a low of -$98886.7 in Q1 2019.
- A 5-year average of $11938.2 and a median of -$9344.6 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests sank 238.78% in 2019 and surged 2846.79% in 2022, its largest moves.
- ProQR Therapeutics' Income from Non-Controlling Interests stood at -$49809.9 in 2019, then soared by 73.67% to -$13115.2 in 2020, then plunged by 65.73% to -$21735.4 in 2021, then surged by 85.92% to -$3060.7 in 2022, then surged by 10414.21% to $315691.2 in 2023.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $315691.2, $17422.8, and $83720.7 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 315,691.24 |
| Jun 30, 2023 | 17,422.79 |
| Mar 31, 2023 | 83,720.66 |
| Dec 31, 2022 | -3,060.74 |
| Sep 30, 2022 | 14,115.84 |
| Jun 30, 2022 | 231,551.30 |
| Mar 31, 2022 | -8,978.70 |
| Dec 31, 2021 | -21,735.45 |
| Sep 30, 2021 | -25,944.32 |
| Jun 30, 2021 | -8,429.90 |
| Mar 31, 2021 | -13,268.60 |
| Dec 31, 2020 | -13,115.19 |
| Sep 30, 2020 | -9,344.62 |
| Jun 30, 2020 | -7,710.22 |
| Mar 31, 2020 | -25,390.60 |
| Dec 31, 2019 | -49,809.95 |
| Sep 30, 2019 | -57,861.96 |
| Jun 30, 2019 | -92,138.41 |
| Mar 31, 2019 | -98,886.71 |
| Dec 31, 2018 | -37,666.08 |
| Sep 30, 2018 | -38,383.26 |
| Jun 30, 2018 | -69,219.78 |
| Mar 31, 2018 | 71,254.90 |
| Dec 31, 2017 | 32,968.11 |
| Sep 30, 2017 | 11,750.63 |